*僅供醫學專業人士閱讀參考

*以下內容僅供醫療衛生專業人士瀏覽。

參考文獻：

[1]Wangxia Lv, et al. A multi-cohort real-world study of treatment for metastatic colorectal cancer (mCRC): Overall efficacy analysis and subgroup analysis of previous bevacizumab use or not. JCO 43, e15530-e15530(2025).

[2]Fukuoka S, et al. J Clin Oncol. 2020;38(18):2053-2061.

[3]JAMA 2018;319(24):1-11.

[4]Lancet 2023;402(10395):41-53.

[5]Qin SK, Li J, Xu RH, et al. To Evaluate the Efficacy of Fruquintinib versus Regorafenib and Trifluridine/Tipiracil in Treating Advanced Metastatic Colorectal Cancer: A Match-adjusted Indirect Comparison. 2025 ASCO. #Abstract.

[6]Xu L, Qu JL, Cheng Y, et al. Real-world Observational Study of Fruquintinib in Combination with Irinotecan and Capecitabine as Second-line Treatment in Patients with Advanced Colorectal Cancer. 2025 ASCO. #Abstract.

[7]Jia R, Wang ZK, Han QL, et al. Preliminary results of fruquintinib in combination with FOLFIRl as second-linetreatment for RAS-mutant metastatic colorectal cancer:a prospective,single-centerphase 2 study. 2025 ASCO. #Abstract.

[8]2024 JSCO. Abstract No.3000184.

[9]JCO 41, 152-152(2023).

[10]2024 ASCO Abstract TPS3643.

NP-AYT-25N485-Valid Until-2027-June

本資料由和黃醫藥提供支持

本資料旨在促進醫藥信息的溝通和交流，而非廣告宣傳。本資料內容不能以任何方式取代專業的醫療指導，也不應被視為診療建議。若您想了解更多有關疾病知識的信息，請咨詢醫療衛生專業人士。

* 此文僅用于向醫學人士提供科學信息，不代表本平臺觀點